| 摘要 |
The present invention relates to a pharmaceutical composition comprising a p-glycoprotein inhibitor and a p-glycoprotein substrate drug. The pharmaceutical composition of the present invention reduces side effects of the drug caused by activity of p-glycoprotein, and further may provide an equivalent pharmacological effect using a smaller amount of the drug. In particular, use of dabigatran etexilate, a p-glycoprotein substrate drug, with tetrazole derivative, a p-glycoprotein inhibitor, can significantly increase the bioavailability of dabigatran etexilate, and consequently the remaining amount of dabigatran etexilate in the gastrointestinal tract may be significantly reduced as the drug has the same level of bioavailability despite a reduction in the amount thereof. Also, because of the above reasons, the dosage of the drug in the gastrointestinal tract is reduced, and so the pharmaceutical composition of the present invention can reduce the risk of bleeding, a fatal drawback for patients taking a conventional dabigatran etexilate. |
